Treatment of warts using heat and hydrogen peroxide
Rrandomized Controlled Clinical Trial Named Mild Local Hyperthermia and Hydrogen Peroxide Treat Multiple Warts by Targeting a Single Lesion.
This study is testing if using heat along with hydrogen peroxide can help people get rid of warts caused by a virus better than using either treatment alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 16 Years to 65 Years |
| Sex | All |
| Sponsor | First Hospital of China Medical University Academic / other |
| Locations | 2 sites (Shenyang, Liaoning and 1 other locations) |
| Trial ID | NCT06812065 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness and safety of combining local hyperthermia at 44°C with a 3% hydrogen peroxide solution for treating viral warts. The study aims to enhance the immune response against HPV-infected lesions by applying heat, which has been shown to mobilize the body's defenses. Participants will be randomly assigned to receive either the combination treatment or individual treatments to assess comparative efficacy. The trial employs a randomized parallel control design and utilizes statistical methods for data analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 16 to 65 with a clinical diagnosis of viral warts.
Not a fit: Patients with atypical warts, immunocompromised status, or those who have recently undergone certain treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective and less painful option for patients suffering from viral warts.
How similar studies have performed: While hyperthermia has been used in other contexts, this specific combination approach with 3% hydrogen peroxide is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: The participants were between 16 and 65 years of age, had a clinical diagnosis of viral warts (including common warts, plantar warts, or condyloma acuminatum), and could understand and sign informed consent. Exclusion criteria: presented with clinically atypical warts; had immunocompromised status or a history of HIV infection; received HPV vaccination within the past 6 months; used immunomodulators, immunosuppressants, or systemic corticosteroids within defined timeframes (4 months and 1 month, respectively); underwent local therapies (e.g., laser, cryotherapy, retinoids) on or near warts within protocol-specified intervals; had a history of cutaneous malignancies or current precancerous lesions; exhibited active dermatologic/systemic diseases (e.g., psoriasis, eczema) or skin conditions (e.g., sunburn) potentially increasing study risks; or were deemed ineligible by investigators for other medical or logistical reasons.
Where this trial is running
Shenyang, Liaoning and 1 other locations
- Guo Hao — Shenyang, Liaoning, China (Recruiting)
- infrared hyperthermia device (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Hao Guo
- Email: guohao27@126.com
- Phone: +86 13840365892
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.